Sagimet Biosciences (SGMT) Return on Capital Employed (2023 - 2026)

Sagimet Biosciences (SGMT) posted quarterly Return on Capital Employed of 45.62% for Q1 2026, up 5.89% quarter-over-quarter from 48.48% in Q4 2025.

Sagimet Biosciences (SGMT) Return on Capital Employed (2023 - 2026) Analysis & Trends

Sagimet Biosciences' Return on Capital Employed history runs 4 years deep, the most recent figure standing at 45.62% for Q1 2026.

In Q1 2026, Return on Capital Employed changed N/A year-over-year to 45.62%; the TTM figure through Mar 2026 stood at 45.62% (changed N/A YoY), while the FY2025 annual figure was 42.69%, up 121.0% from the prior year.
Return on Capital Employed for Q1 2026 stood at 45.62%, up from 48.48% in the prior quarter.
The five-year high for Return on Capital Employed was 32.64% in Q4 2023, with the low at 51.97% in Q3 2025.
The 4-year median for Return on Capital Employed is 48.48% (2025), against an average of 44.57%.
The sharpest annual moves came in 2024 and 2025: Return on Capital Employed plunged 75 bps in 2024, then sank 1509 bps in 2025.
Sagimet Biosciences' Return on Capital Employed stood at 32.64% in 2023, then retreated by 2 bps to 33.39% in 2024, then sank by 45 bps to 48.48% in 2025, then advanced by 6 bps to 45.62% in 2026.
Business Quant data shows SGMT's Return on Capital Employed at 45.62% in Q1 2026, 48.48% in Q4 2025, and 51.97% in Q3 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	ROCE (Qtr)
1	Vertex Pharmaceuticals	128.13 Bn	120.28 Bn	2.84 Bn	20.76%
2	Regeneron Pharmaceuticals	112.33 Bn	104.33 Bn	3.93 Bn	10.74%
3	Argenx Se	53.24 Bn	48.05 Bn	1.41 Bn	-
4	Revolution Medicines	43.64 Bn	43.64 Bn	-	-55.45%
5	BeOne Medicines	39.27 Bn	34.17 Bn	1.53 Bn	13.68%
6	MindWalk Holdings	35.32 Bn	35.31 Bn	1.82 Bn	-0.20%
7	Royalty Pharma	33.72 Bn	35.84 Bn	-	7.88%
8	Alnylam Pharmaceuticals	30.58 Bn	27.27 Bn	992.69 Mn	26.09%
9	Insmed	27.01 Bn	25.85 Bn	358.27 Mn	-50.93%
10	Sagimet Biosciences	649.79 Mn	649.79 Mn	-	-29.21%

Download Data